Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European Osteosarcoma Intergroup
Lewis, Ian J × Nooij, Marianne A Whelan, Jeremy Sydes, Matthew R Grimer, Robert Hogendoorn, Pancras C. W Memon, Muhammad A Weeden, Simon Uscinska, Barbara M van Glabbeke, Martine Kirkpatrick, Anne Hauben, Esther Craft, Alan W Taminiau, Antonie H. M #
Oxford University Press
Journal of the National Cancer Institute vol:99 issue:2 pages:112-128
Background Previous randomized controlled trials that used the two-drug chemotherapy regimen of cisplatin and doxorubicin as the conventional arm showed no evidence of benefit from an increase in the number of agents or the length of treatment. It was then proposed that survival could be improved by increasing the planned dose intensity of cisplatin and doxorubicin.